Iovance Stock Plunges Despite Amatuviv Canada Approval
Iovance, a biotechnology company, has received its first approval outside the US for Amatuviv in Canada. However, the stock market is reacting negatively due to weak sales and a bearish sentiment.
On October 14, a new analysis from Börse Express suggested whether investors should buy or sell Iovance stock. Despite this guidance, the stock market is punishing Iovance due to poor Amatuviv sales and negative trends, as indicated by technical indicators.
Iovance is maintaining its annual revenue forecast of $250 to $300 million, with a projected net cash burn of less than $245 million by the second quarter of 2026. In the second quarter of 2025, the company reported total revenue of $60.0 million, a loss per share of ($0.33), and liquidity of $307.1 million.
To boost revenue, Iovance is pursuing international approvals and resuming talks with the Yahoo Finance. The company is also driving its clinical programs forward, planning to present new data for its lung cancer study IOV-LUN-202 in the second half of 2025.
Iovance is facing a stock crisis due to massive restructuring, missed earnings expectations, and a downward trend. To secure liquidity until the fourth quarter of 2026, the company is implementing a restructuring program that aims to save over $100 million annually, including a 19% reduction in jobs in the third quarter.
